How we helped determine the next groundbreaking development in a hard-to-treat respiratory disease
Our client wanted to understand the current management in a complex therapy area, as treatment regimens require a combination of multiple drugs. Furthermore, the disease is most prevalent in emerging, hard-to-access markets. Understanding of drugs and treatment regimen preferences were required to help gauge likely success of the client’s new formulation in development, which would be part of a new regimen paradigm. As well as understanding current preferences and reactions to the new drug and regimen, the research needed to test several potential outcomes for the new formulation and assess performance against future new regimens likely to be available at the time of launch.
Living With: The journey from the patient’s perspective
Our new interactive infographic reveals insights into the patient journey across a range of chronic diseases.
“Living With” is a series of reports based on quantitative market research with patients, providing comprehensive and cost-effective insight into the patient journey from pre-diagnosis to stabilisation. These reports are invaluable for pharma companies wishing to adopt a more patient-centric approach.
Real world evidence research breakfast seminar
We were delighted to attend and present a paper at the Tech Observer event in Singapore earlier this month
APAC Director Pei Li Teh, and Research Manager, Colin Tan, attended the event. Pei Li presented the paper ‘Inhale, exhale: How using real world data helped asthma patients breathe easier across Asia’. In her paper she demonstrated how published real world data research provided pharma companies with an in-depth understanding of asthma patients’ across Asia. The data provided the healthcare community with a tool to supply tailored communications supporting different patient types, instead of a ‘one size fits all’ approach.
Research Partnership welcomes Jeanne Penn
We are delighted to announce that Jeanne Penn has joined the Singapore office as a Senior Research Executive.
Jeanne previously worked at Cello Health Insight in New York City on the qualitative team, where she was involved in all parts of the research process, from writing proposals to delivering reports. She’s worked in various therapy areas, and has a particular interest in rare diseases and mental health. In a prior role, she co-led the first Diversity & Inclusion initiative and was awarded the Young Professionals Grant to attend the Qualitative Research Consultants Association (QRCA) conference. Jeanne graduated from Hamilton College, and interned at Hall & Partners where she was first introduced to healthcare market research.
How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful benefits to patients and contribute to the overall growth of their business.